HONG KONG, April 18, 2026 /PRNewswire/ — Phase II of the Global Sources Hong Kong Shows opened today at AsiaWorld-Expo, running from 18 to 21 April over four consecutive days. The show comprises four major professional trade shows: the Mobile Electronics Show, the Smart Home, Security & Home Appliances Show, the Lifestyle Show, and the Home & Kitchen Show, bringing together over 2,000 quality suppliers across nearly 4,000 booths and showcasing approximately 150,000 new products spanning mobile devices, smart wearables, AR/VR, smart home solutions, personal healthcare, pet products and more. Notably, the number of mobile accessories exhibitors has grown by 50% compared with the same period in 2025. As of March, global pre-registered buyers grew 35% year on year, with particularly strong increases from Eastern Europe, Western Europe, the United States and ASEAN.

Global Sources Hong Kong Shows Phase II includes:

• Global Sources Mobile Electronics
• Global Sources Smart Home, Security & Home Appliances
• Global Sources Lifestyle
• Global Sources Home & Kitchen

As the global consumer electronics industry undergoes a structural transformation driven by AI, Hong Kong’s role as an international sourcing hub is evolving in tandem. John Kao, Vice President of Hong Kong Shows & Overseas Shows at Global Sources, said: “AI is moving from concept to mass production — the wave of technology reshaping products has arrived. The biggest change at this year’s show is that AI is no longer confined to a standalone tech zone; it has permeated virtually every product category, from smart wearables and home security to personal healthcare. AI has become the core driving force behind product upgrades. For global buyers, this is a pivotal opportunity to lock in future product trends and uncover new growth opportunities.”

AI Products Reach Market Faster — Over 1,200 Booths Dedicated to AI
The “AI Pavilion”, where the AI products most readily making their way into everyday life, brings together over 1,200 booths showcasing smart products with proven mass-production capabilities across seven key segments: AI terminal devices, AI wearables, AI glasses, AI toys, AI pet products, AI personal healthcare and AI convergence products, offering a one-stop overview of the latest breakthroughs in AI hardware ecosystems. The zone also introduces the “Physical.ai Lab” for the first time. In line with China’s designation of humanoid robots as a strategic emerging industry, the lab showcases robot products that have already entered the commercialisation stage, including humanoid robots, embodied intelligent robots, robotic lawn mowers and educational robots, marking the full extension of AI decision-making capabilities from virtual spaces into complex physical mobility and operational scenarios. For global buyers, this is not merely a technology showcase but a sourcing opportunity for commercially viable automation solutions.

AI is redefining the product logic of traditional consumer electronics — transforming what were once function-driven products that simply executed commands into “demand-sensing products” capable of interpreting user behaviour and delivering personalised services, illustrating the entirely new industry landscape that emerges when AI becomes a product standard. At the same time, exhibits in traditional category zones demonstrate the deep-rooted strengths of the supply chain, with a focus on energy efficiency improvements, design optimisation, material upgrades and manufacturing process refinements, reflecting mature capabilities in scaled production, lean manufacturing and global fulfilment.

Innovation Awards Introduce “AI Innovation Award” — Global Product Launches Converge on Hong Kong
The Global Sources Innovation Awards for Phase II spotlight products across mobile electronics, smart home, security and appliances, and lifestyle categories, recognising outstanding innovations in practicality, cost-effectiveness, technological maturity and market relevance. Global Sources once again partners with the internationally renowned “European Product Design Award (EPDA)™” to present the “Best Product Design Award”, honouring products that stand out through innovative thinking and exceptional design. To align with AI’s emergence as an industry mainstay, Phase II introduces the “AI Innovation Award”, recognising exhibits that demonstrate excellence in AI technology application.

In addition, Phase II host multiple new product launch events, with numerous exhibitors using this platform to unveil their annual innovations, including heavyweight global and Asian debuts that further cement the Hong Kong Shows’ position as the world’s premier stage for consumer electronics product launches.

Industry Leaders Gather to Decode AI-Enabled Business Pathways
Running concurrently with the show, the Global Sources Summit and “AI & Robotics Summit (AIRS)” bring together leading global industry experts to explore cutting-edge topics including AI-driven retail markets, smart sourcing strategies, operational intelligence, consumer insights and next-generation technology innovation, providing in-depth analysis of how AI is restructuring the consumer electronics value chain and helping the industry seize business opportunities in the shift from “smart” to “intelligent”. The summit programme features “The AI Gold Rush” session on 19 April and the “Consumer Tech Futures” session on 20 April. An on-site AI robot demonstration area allows visitors to experience human-machine interaction and live demonstrations up close, including a performance by Linkerbot’s robot band and dance and kung fu demonstrations by Unitree robots, showcasing advanced capabilities in motion planning and real-time control while exploring the commercial potential of robotics in entertainment, services and beyond.

Comprehensive Buyer Service Upgrades Drive Precise Matching and Trade Collaboration
To further enhance the buyer sourcing experience, this edition of the show introduces a number of new services. The upgraded Business Matching service is expected to arrange over 3,000 buyer-supplier matching sessions across all three phases, facilitating collaboration between global buyers with clear sourcing intent and quality suppliers. A Sourcing Connection Desk has been set up on-site for the first time, providing comprehensive support to help buyers locate target exhibitors and arrange on-the-spot matching — offering real-time assistance for buyers who were unable to book appointments in advance. In addition, the Hong Kong Show website has launched a new Meet the Exhibitors page, allowing buyers to search by show, product, country or region, with features to contact exhibitors and add events to their calendars for more effective sourcing trip planning. The Global Sources Buyer App has also been fully optimised to deliver a simpler, more personalised user experience that puts information at buyers’ fingertips. The show expects to welcome close to 900 new overseas buyers to participate in on-site matching and networking activities, including high-quality buyers from Western Europe, the United States, Japan and ASEAN.

About Global Sources
Based in Hong Kong, Global Sources is a globally recognised B2B sourcing platform. With 55 years of dedicated service in facilitating international trade, it has earned the trust and recognition of the global business community through its proven track record of connecting quality buyers worldwide with verified top-tier Asian manufacturers. As a sourcing hub for market-ready innovative consumer products, Global Sources provides efficient and convenient trade services to over 14 million registered buyers and users worldwide.

KUALA LUMPUR, Malaysia, April 18, 2026 /PRNewswire/ — Ddrops® participated in the annual Sports Day hosted by Dripping Colours Montessori on April 18, 2026, reinforcing its commitment to supporting children’s healthy growth through active lifestyles and proper nutrition.

Serving children aged 2 to 6, Dripping Colours Montessori integrates Montessori principles that emphasize child-led learning, hands-on exploration, and holistic development. The Sports Day extended learning beyond the classroom, encouraging children to build physical strength, confidence, and resilience through movement and play.

Early childhood is a critical stage of growth, where proper nutrition plays a key role in supporting bone development, immune function, and overall well-being. Nutrients such as vitamins D and A are essential for helping children stay active and engaged in their daily learning experiences.

Aligned with this philosophy, Ddrops® offers a simple approach to daily supplementation. Its “one drop a day” format provides an easy and effective way for families to deliver essential nutrients, including vitamins A and D3, supporting calcium absorption, immune health, and eye health.

During the event, Ddrops® engaged with families through interactive activities and curated giveaways, helping parents better understand how to incorporate nutritional support into everyday routines.

Originating from Canada, Ddrops® is known for its clean formulations, free from added sugars, preservatives, artificial colors, and common allergens.

As the No. 1 pediatrician-recommended brand in Canada, Ddrops® is backed by a range of international certifications, including the Mom‘s Choice Award, GMP, NPN, NSF, SGS, USDA Organic, NPRA Certification, and HMA Halal, underscoring its commitment to quality and safety.

Its Vitamin A & D3 range was named “Best Liquid Vitamin A & D3 Supplement” at the 2025 Motherhood Choice Awards, while its Vitamin D3 range earned “Best Family Vitamin D Supplement” in 2024.

As Ddrops® continues to expand across Southeast Asia, it remains focused on providing safe, convenient, and high-quality nutritional solutions, supporting families in building strong foundations for children’s healthy development.

GUANGZHOU, China, April 18, 2026 /PRNewswire/ — On April 15, the 139th Canton Fair opened in Guangzhou. As one of the world’s largest trade events, it gathers global buyers and leading manufacturers. TAILG participated under “Tech TAILG. Leading Globally,” presenting its full lineup of flagship products and demonstrating strength in electric mobility and global development.

On the opening day, TAILG appeared with one of the largest booth areas in the exhibition hall. Visitor traffic remained high throughout the day. Buyers from Europe, the Americas, and other regions—including new and long-term partners—visited the booth, highlighting TAILG’s global appeal.

Frontier Tech and Flagship Products

At the exhibition, TAILG showcased 22 models, including electric motorcycles, e-bikes, electric bicycles, and electric tricycles, meeting diverse mobility needs across global markets.

The F91 Ultra-L fast-charging model made a key appearance, featuring automotive-grade fast-charging technology and an integrated “vehicle + charging station” solution. It offers up to 150 km range and is equipped with a 50,000cd intelligent headlight and a TCS traction control system, delivering balanced performance in power, safety, and lighting.

The upgraded F55 model also attracted attention, featuring a refreshed design and optimized power system, further strengthening its competitiveness in global markets.

Global Presence and Trust

TAILG focuses on real-world mobility needs, optimizing product performance and supply capabilities worldwide. With years of overseas experience, its products have achieved stable performance in markets such as Vietnam, Iraq, and Morocco, supported by expanding distribution networks.

As a partner of the United Nations in electric mobility, TAILG participates in global low-carbon initiatives with international organizations to promote sustainable transport solutions.

Global Strategy

TAILG’s global leadership is built on its integrated R&D, manufacturing, and sales system. The company operates a national-level CNAS laboratory and a global low-carbon mobility research institute, holding over 2,000 patents and multiple international design awards.

It has established seven global R&D and production bases with an annual capacity of over 10 million units, ensuring stable global supply. Its retail network spans more than 27,000 stores across over 70 countries and regions.

Through continuous expansion, TAILG is strengthening its position in the electric mobility industry.

From the Canton Fair, TAILG accelerates global expansion through innovation. Looking ahead, the brand will deepen its global presence, enhance competitiveness, and expand its international market reach.

Debut marks a major milestone in NAVEE’s global expansion and growing focus on U.S. market

MONTEREY, Calif., April 17, 2026 /PRNewswire/ — NAVEE, a global smart mobility brand, announced its official entry into the U.S. e-bike market at the Sea Otter Classic, one of North America’s most influential cycling events. NAVEE introduced eight e-bike series: Urban, Fold, Compa, Speed Pedelec, Bison, Gravel, Storm, and Cyber.

Since 2021, NAVEE has become one of the fastest-growing micro-mobility brands globally, ranking top three in Europe and No. 1 in the Nordic market. Backed by 447 million miles of real-world riding data and over one million riders across 60+ countries, the company is now bringing that same expertise to e-bikes — a strategic move into the U.S. market.

NAVEE is expanding beyond urban commuting into the broader outdoor mobility landscape, with e-bikes at the heart of that evolution. Millions of American riders are embracing new ways to move, from daily commutes to weekend adventures. NAVEE is here to meet that momentum with e-bikes engineered for the way you actually ride.

“Since day one, NAVEE has focused on making everyday mobility easier and more enjoyable through thoughtful design and practical innovation,” said Eric Tian, Head of NAVEE E-bikes. “We see the U.S. as a key growth market and are committed to meeting the everyday needs of riders here.”

Highlighted models at Sea Otter Classic 2026:

Speed Pedelec SP01: Designed for riders who want to go further, faster, with less effort. Delivers 1000W rated power and 100Nm torque for effortless climbing and speeds up to 28mph. Auto-shift transmission adjusts gears automatically.

Gravel Ultra 01: Built for pavement and gravel. Torque sensor technology delivers direct pedal response, while Shimano 10-speed gearing handles the rest.

Bison Core 01: A 48V/750W motor delivers strong acceleration up to 28 mph. Its 20-inch folding frame and puncture-resistant all-terrain tires handle city streets and mixed terrain with ease.

NAVEE also showcased its electric scooter lineup at Sea Otter Classic, including the UT5 Ultra X, UT5 Max, NT5 Ultra X, and GT5 Max — all well received by attendees and demonstrating NAVEE’s full range of smart mobility solutions.

The Storm is now available in the U.S., the Cyber and more models are coming soon. Visit naveetech.us and search “Storm” to learn more.

Media Contact:
Cecilia
NAVEE E-bike PR Manager
wangpeng19@navee.tech

The strategic collaboration brings together METT Singapore’s luxury event spaces, The MasterPlan LLP’s commercial and programme expertise, and UPGroup Asia’s AVL production, technical expertise, and integrated venue operations capabilities to deliver seamless, high-impact events at scale, strengthening the venue’s position in the MICE and premium events landscape.

SINGAPORE, April 18, 2026 /PRNewswire/ — METT Singapore, UPGroup Asia, and The MasterPlan today announced a strategic partnership agreement that brings together the lifestyle hotel’s luxury event spaces with UPGroup Asia’s advanced AVL production capabilities and The MasterPlan LLP’s expertise in high-value business events. The agreement was signed on 17 April 2026 at METT Singapore, 11 Canning Walk, Singapore, during METTUP 2026, a networking event for professionals from the MICE, hospitality and events industries.

Under the partnership, UPGroup Asia joins METT Singapore as its preferred AVL partner, delivering audio, visual, lighting, and livestream production solutions for events at the venue, while activating its Venue Management Programme to elevate the venue’s event operations.

“METT Singapore has the spaces and the character that corporate clients are increasingly looking for. Our role is to make sure the production side is seamless, so that the technical execution never gets in the way of the experience. Having The MasterPlan alongside us means that clients also have access to programme design and stakeholder management expertise from day one. That combination means clients have everything they need to deliver a high-quality event experience, in a venue that is already built for it.”

—  Adam Piperdy, Founder & Chief Experience Officer, UPGroup Asia

The MasterPlan, specialising in business-to-business events including conferences, seminars, product and media launches, C-level meetings, and curating customer experiences, takes on the role of preferred B2B event agency and programme partner, supporting event organisers in designing and executing programmes at METT Singapore.

“Our clients want venues that can deliver on the full promise of an event: the setting, the programme, and the production. METT Singapore gives us that setting, and working alongside UPGroup Asia means the production capability is already in place. For meeting planners and corporate clients looking for a venue that is both distinctive and operationally ready, METT Singapore delivers on both.”

— Jasmine Ho, Founder & Managing Partner, The MasterPlan LLP

The collaboration strengthens METT Singapore’s position as a destination of choice for corporate and MICE events. With UPGroup Asia’s audio, visual, and lighting solutions embedded across its event operations, METT Singapore is equipped to deliver seamless, high-impact experiences at every scale. Through The MasterPlan LLP’s enterprise client relationships and programme expertise, the venue becomes a natural destination for meeting planners, corporate clients, and premium brands seeking a distinctive address for their most important events.

“At METT Singapore, we have always believed in creating spaces that bring people together—thoughtfully designed to foster connection, engagement, and meaningful experiences. Partnering with UPGroup Asia and The MasterPlan LLP allows us to bring this vision to life, combining our environment with the production capabilities and event expertise that today’s corporate and MICE clients expect. We look forward to welcoming more organisations to experience all that METT Singapore has to offer.” 

— Marcel Li, General Manager, METT Singapore

METT Singapore is located within Fort Canning Park and is operated by Sunset Mett Sing Pte. Ltd. under the Sunset Hospitality Group. The hotel features 84 rooms and suites, a 950-square-metre Grand Ballroom and a 360-square-metre Junior Ballroom, alongside outdoor terrace spaces, offering a design-led environment for high-value corporate and luxury events.

ABOUT THE ORGANISATIONS

About UPGroup Asia

UPGroup Asia is an integrated event experience agency delivering event experiences in Singapore and Asia. Empowered by a team of creators, strategists, and experts who are deeply passionate about content, audience engagement, and event technology, UPGroup Asia delivers a complete suite of event solutions that allow event organisers to seamlessly execute award-winning event experiences. Producing hundreds of event experiences for thousands of audiences annually, UPGroup Asia is the trusted partner of both organisations and venue owners in the region.

About The MasterPlan LLP

At The MasterPlan, we specialise in the art of the B2B experience. We take the complexity of conferences, the wow moments at product launches, the prestige of CXO engagements, and the energy of brand activations, and distill them into a single, flawless execution. We cherish long-term partnerships and our clients’ brand and marketing objectives. Thus translating these understandings to great experiences and seamless execution onsite.

About METT Singapore

METT Singapore is a stylish 5-star city escape surrounded by nature that blends elegant colonial charm with contemporary soul. Nestled within the lush, historic grounds of Fort Canning Park, yet steps from Orchard Road, METT presents a destination where heritage meets high energy, social connections are celebrated, and next-generation wellness is embraced.

The iconic listed property, which celebrates its 100th anniversary this year offers 84 elegant and light-filled suites and rooms and bespoke event spaces designed to inspire unforgettable moments. At the heart of the experience is dining as a social ritual led by Michelin-starred Chef Daniele Sperindio, offering four distinctive concepts including L’Amo Bistrò del Mare, an ode to premium Italian coastal dining.

Hotel guests enjoy access to Madison House private members club, with two sparkling swimming pools, three padel and pickleball courts, a state-of-the-art fitness studio and wellness by The Longevity Suite.

MEDIA CONTACTS

UPGroup Asia
Josiah Eufemio  |  Marketing & Communications Lead  |  josiah_eufemio@upgroup.asia

The MasterPlan LLP
Laiyee Wong  |  Senior Project Manager  |  laiyee@themasterplan.com.sg

METT Singapore
Glenda Raphaela Dharma | Assistant Marketing Manager – Hotel | glenda.dharma@metthotelsandresorts.com

SHANGHAI and HONG KONG, April 18, 2026 /PRNewswire/ — Antengene Corporation Limited  (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that it has released present results from three novel programs in poster presentations at the 2026 American Association for Cancer Research Annual Meeting (AACR 2026). The presentations will feature ATG-125 (B7-H3 x PD-L1 bispecific antibody-drug conjugate [ADC]), an IO + ADC dual-function molecule being developed for the treatment of solid tumors, as well as two investigational T cell engagers (TCEs) developed using the company’s proprietary AnTenGager^® TCE platform, including ATG-106 (CDH6 x CD3 TCE) for ovarian and kidney cancers, and ATG-112 (ALPPL2 x CD3 TCE) for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC.

Details of the Poster Presentation:
ATG-125 (B7-H3 x PD-L1 bispecific ADC)
Title: ATG-125, a novel B7H3 x PD-L1 bispecific antibody-drug conjugate, demonstrates potent antitumor efficacy by dual targeting of immune evasion and direct tumor killing
Abstract Number: 5599
Session Category: Immunology
Session Title: T Cell Engagers 2 / Antibody-Drug Conjugates 1
Date: April 21, 2026
Time: 02:00 PM – 05:00 PM (Pacific Time)
           05:00 AM, April 22, 2026 – 08:00 AM, April 22, 2026 (Beijing Time)
Location: Poster Section 8

• Introduction: B7-H3 and PD-L1 are immune checkpoint molecules broadly overexpressed across multiple solid tumors and are associated with immune evasion and poor prognosis. Although PD-1/PD-L1-directed therapies have demonstrated clinical benefit, treatment resistance remains a significant challenge. B7-H3 is also emerging as a promising ADC target due to its broad tumor expression and rapid internalization. ATG-125 is a novel B7-H3 x PD-L1 bispecific ADC designed to combine direct tumor killing with immune activation by co-targeting two complementary tumor-associated pathways in a single molecule.
• Results: ATG-125 bound to both B7-H3 and PD-L1 with high specificity and nanomolar affinity and demonstrated robust antigen-dependent internalization in dual-positive tumor cells, enabling efficient intracellular payload release. The molecule induced tumor cell apoptosis, while its parental naked antibody blocked PD-1/PD-L1 interaction and elicited IL-2 and IFN-γ production in mixed lymphocyte reaction assays. ATG-125 also enhanced T-cell activation, as reflected by an increased ratio of CD69+/CD3+ T cells in co-cultures of tumor cells and human PBMCs. In vivo, ATG-125 demonstrated sustained antitumor activity in HCC827 xenograft models, increased tumor infiltration of CD4+ and CD8+ T cells in PBMC-humanized models, and inhibited tumor growth in a dose-dependent manner in MC38-hB7H3 syngeneic models, accompanied by elevated intratumoral CD8+ T-cell infiltration.
• Conclusion: ATG-125 demonstrated synergistic IO+ADC antitumor activity through a differentiated mechanism combining enhanced internalization for payload delivery with the potential to restore anti-tumor immunity. Its compelling preclinical profile supports further development for patients with solid tumors.

ATG-106 (CDH6 x CD3 TCE)
Title: ATG-106, a novel “2+1” format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy
Abstract Number: 1621
Session Category: Immunology
Session Title: T Cell Engagers 1
Date: April 20, 2026
Time: 09:00 AM – 12:00 PM (Pacific Time)
           00:00 AM, April 21, 2026 – 03:00 AM, April 21, 2026 (Beijing Time)
Location: Poster Section 10

• Introduction: CDH6 plays an important role in embryonic kidney development but has negligible expression in adult kidney tissue. Its overexpression in ovarian and renal cancers, together with limited normal tissue expression, makes CDH6 an attractive therapeutic target. However, T cell engagers in solid tumors have often been limited by insufficient efficacy and the risk of cytokine release syndrome. To address these challenges, Antengene developed ATG-106, a novel “2+1”, sterically masked CDH6 x CD3 bispecific TCE designed to deliver potent antitumor activity with the potential for a reduced CRS risk profile.
• Results: ATG-106 exhibited reduced binding affinity to CD3+ cells before CDH6 crosslinking, while inducing approximately 100- to 400-fold more potent cytotoxicity against CDH6-positive tumor cells compared with a “1+1” CrossMab control TCE. The molecule demonstrated potent T cell-dependent cytotoxicity in ovarian and renal cancer models and showed low immunogenicity risk in vitro. In PBMC-humanized 786-O kidney cancer xenograft models, ATG-106 induced tumor shrinkage in all treated mice, with complete remissions observed in the 0.1 mg/kg and 0.3 mg/kg groups. ATG-106 also induced tumor shrinkage and complete remission in PBMC-humanized OVCAR-3 ovarian cancer models. Notably, pro-inflammatory cytokine levels remained very low in treated animals, suggesting low CRS risk. In non-human primate studies, the surrogate molecule ATG-106-RM was well tolerated at doses up to 10 mg/kg.
• Conclusion: ATG-106 demonstrated limited T cell binding in the absence of target cells, potent cytotoxicity against tumor cells, and encouraging in vivo efficacy in ovarian and kidney cancer models. Favorable safety findings with the surrogate molecule in non-human primates further support continued clinical development of ATG-106 as a CDH6-targeted TCE candidate.

ATG-112 (ALPPL2 x CD3 TCE)
Title: ATG-112, a novel ALPP/G x CD3 bispecific T cell engager, for the treatment of ALPP/G⁺ solid tumors
Abstract Number: 1620
Session Category: Immunology
Session Title: T Cell Engagers 1
Date: April 20, 2026
Time: 09:00 AM – 12:00 PM (Pacific Time)
           00:00 AM, April 21, 2026 – 03:00 AM, April 21, 2026 (Beijing Time)
Location: Poster Section 10

• Introduction: Placental alkaline phosphatase and related placental-like/germ-cell isoforms, including ALPPL2 and ALPG, are aberrantly expressed in a range of solid tumors while being largely absent from normal adult tissues except the placenta, making them highly promising tumor-selective immunotherapy targets. Antengene developed ATG-112, an ALPP/G x CD3 bispecific TCE based on the AnTenGager^® platform in a “2+1” format, featuring bivalent antigen binding to improve low-antigen tumor recognition and a sterically masked CD3 binding arm designed to restrict T-cell activation to the tumor microenvironment.
• Results: Tissue microarray IHC analysis showed that ALPP/G expression was restricted to placental tissue among normal organs and was not detected in other normal tissues, while frequent expression was observed in endometrial and ovarian cancers, with lower prevalence in bladder, gastric and pancreatic cancers. ATG-112 demonstrated high binding affinity to both ALPP/G-positive tumor cells and recombinant proteins, with EC50 and KD values in the sub-nanomolar range. It induced robust T cell-dependent cytotoxicity against target-positive cells with picomolar EC50 values, while in vitro cytokine-release assays showed minimal cytokine secretion from human PBMCs. In vitro studies also demonstrated that the spatial masking effect of ATG-112 is reversible. Immunogenicity assessment showed low immunogenic potential, and in vivo ATG-112 delivered potent tumor suppression across multiple dose levels in humanized mouse models, with low cytokine release and controllable CRS risk at efficacious doses. The program also demonstrated strong developability characteristics.
• Conclusion: ATG-112 demonstrated a compelling preclinical profile, with potent in vitro and in vivo antitumor activity and minimal cytokine release. These findings support the continued advancement of ATG-112 toward clinical development for solid tumors.

About Antengene
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), and ATG-125 (B7-H3 × PD-L1 bispecific ADC).

Antengene has also developed AnTenGager^®, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO^® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com